We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01215214
Recruitment Status : Completed
First Posted : October 6, 2010
Last Update Posted : February 23, 2011
Information provided by:

Study Description
Brief Summary:
Identification and evaluation of endogenous markers for the assessment of CYP3A activity using metabolomics.

Condition or disease Intervention/treatment Phase
Healthy Drug: midazolam Phase 1

Detailed Description:
Eligibility for participation of this study will be determined from demographic information, medical history, physical examination, electrocardiogram (ECG) and clinical laboratory tests within 3 weeks before study drug administration. Subjects suitable for this study will be admitted to the Clinical Trials Center, Seoul National University Hospital on the day before dosing, and they were overnight-fasted from 10 p.m. of Day -1. Urine collection is scheduled drug 24 hour before midazolam administration. Subjects will be dosed study drug via intravenous around at 9 a.m. of Day 1. Subjects performed scheduled procedures including clinical laboratory tests, electrocardiograms and pharmacokinetic samplings. Subjects will be discharged on Day 2, and visited Clinical Trials Center on Day 5-7 for ketoconazole administration. Subjects will be admitted on Day 7 for period 2. Subjects performed scheduled period 2 (ketoconazole co-administration phase), and period 3 (rifampicin co-administration phase) procedure. Study participation was terminated on post-study visit (Day 30-32).

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity Using Metabolomics
Study Start Date : October 2010
Primary Completion Date : November 2010
Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: midazolam
period 1: midazolam administration alone period 2: ketoconazole 400 mg PO for 4 days administration, midazolam iv single administration period 3: rifampicin 600 mg PO for 9 days administration, midazolam iv single administration
Drug: midazolam
midazolam: 3mg iv
Other Name: Bukwang midazolam, Korea

Outcome Measures

Primary Outcome Measures :
  1. Metabolomic profile [ Time Frame: -24- -12h, -12- 0h of every midazolam dosing ]
    endogenous metabolite profiles such as steroids

Secondary Outcome Measures :
  1. Pharmacokinetics [ Time Frame: 0h, 10m, 20m, 30m, 45m, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h ]
    Cmax, AUClast of midazolam

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age: Between 20 to 50 years of age, inclusive
  • Weight: Between 50 - 95 kg, within 17-28 of Body Mass Index
  • Subject who are reliable and willing to make themselves available during the study period, are willing to follow the study protocol, and give their written informed consent voluntarily

Exclusion Criteria:

  • History of hypersensitive reaction to medication (midazolam, ketoconazole, rifampicin)
  • History of significant clinical illness needs medical caution, including cardiovascular, immunologic, hematologic, neuropsychiatric, respiratory, gastrointestinal, hepatic, or renal disease or other chronic disease History or evidence of drug abuse
  • Use any prescriptive medication, Korean traditional medication not considered acceptable by the clinical investigator during the last 14 days period before first dosing, or use any OTC medication not considered acceptable by the clinical investigator during the last 7 days period before first dosing (if used medication is considered acceptable by investigator, patients can be included)
  • Participation in clinical trials of any drug within 60 days prior to the participation of the study
  • Judged to be inappropriate for the study by the investigator
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01215214

Korea, Republic of
Seoul National University Hospital
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
Seoul National University Hospital
Ministry of Education Science and Technology, Korea
Principal Investigator: Joo-Youn Cho, PhD Seoul National University Hospital
More Information

Responsible Party: Joo-Youn Cho, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT01215214     History of Changes
Other Study ID Numbers: SNUCPT10_CYP3A
First Posted: October 6, 2010    Key Record Dates
Last Update Posted: February 23, 2011
Last Verified: February 2011

Keywords provided by Seoul National University Hospital:
metabolite profiles

Additional relevant MeSH terms:
Adjuvants, Anesthesia
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
Anesthetics, Intravenous
Anesthetics, General
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action